APP, which was decreased in ALS in our study, has been proposed to be involved in several human neurodegenerative diseases such as AD, autism, fragile X syndrome (FXS), ALS, multiple sclerosis (MS), and Lesch–Nyhan disease (LND) [50]. This evidence concerns the gene APP and myeloid sarcoma.